Pneumocystis pneumonia

Walter T. Hughes

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The diffuse bilateral pneumonitis caused by Pneumocystis jirovecii (also called Pneumocystis carinii) occurs almost exclusively in immunocompromised patients with cancer, organ transplantation, congenital immunodeficiency disorders, and acquired immunodeficiency syndrome (AIDS). The organism is known to cause pneumonitis occasionally in patients without underlying immunodeficiency. CLINICAL FEATURES: The clinical manifestations of Pneumocystis pneumonitis are fever, cough, tachypnea, and dyspnea progressing to cyanosis. The onset may be abrupt or subtle. With an abrupt onset, fever, marked increase in respiratory rate, and severe dyspnea occur within 24 to 48 hours. The disease progresses rapidly with marked decrease in arterial oxygen tension (PaO2) and increase in alveolar-arterial oxygen gradient. The chest radiograph shows bilateral diffuse alveolar disease with an air bronchogram. Without treatment, the disease worsens and within a month all patients will have died. Even in fatal cases and even in the most severely compromised host, the organism and the disease remain localized to the lung, with rare exception. When specific and supportive treatment is introduced early in the disease, the mortality rate can be reduced to around 10% in most medical centers. Abrupt onset tends to occur in patients with cancer, organ transplantation, and AIDS.

Original languageEnglish (US)
Title of host publicationClinical Infectious Disease
PublisherCambridge University Press
Pages1229-1232
Number of pages4
ISBN (Print)9780511722240, 9780521871129
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Pneumocystis Pneumonia
Pneumocystis carinii
Pneumonia
Organ Transplantation
Dyspnea
Acquired Immunodeficiency Syndrome
Fever
Pneumocystis
Oxygen
Tachypnea
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Cyanosis
Immunocompromised Host
Respiratory Rate
Cough
Neoplasms
Arterial Pressure
Thorax
Air
Lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hughes, W. T. (2010). Pneumocystis pneumonia. In Clinical Infectious Disease (pp. 1229-1232). Cambridge University Press. https://doi.org/10.1017/CBO9780511722240.179

Pneumocystis pneumonia. / Hughes, Walter T.

Clinical Infectious Disease. Cambridge University Press, 2010. p. 1229-1232.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hughes, WT 2010, Pneumocystis pneumonia. in Clinical Infectious Disease. Cambridge University Press, pp. 1229-1232. https://doi.org/10.1017/CBO9780511722240.179
Hughes WT. Pneumocystis pneumonia. In Clinical Infectious Disease. Cambridge University Press. 2010. p. 1229-1232 https://doi.org/10.1017/CBO9780511722240.179
Hughes, Walter T. / Pneumocystis pneumonia. Clinical Infectious Disease. Cambridge University Press, 2010. pp. 1229-1232
@inbook{34860b58446f4ab49f0b5288084aa6e8,
title = "Pneumocystis pneumonia",
abstract = "The diffuse bilateral pneumonitis caused by Pneumocystis jirovecii (also called Pneumocystis carinii) occurs almost exclusively in immunocompromised patients with cancer, organ transplantation, congenital immunodeficiency disorders, and acquired immunodeficiency syndrome (AIDS). The organism is known to cause pneumonitis occasionally in patients without underlying immunodeficiency. CLINICAL FEATURES: The clinical manifestations of Pneumocystis pneumonitis are fever, cough, tachypnea, and dyspnea progressing to cyanosis. The onset may be abrupt or subtle. With an abrupt onset, fever, marked increase in respiratory rate, and severe dyspnea occur within 24 to 48 hours. The disease progresses rapidly with marked decrease in arterial oxygen tension (PaO2) and increase in alveolar-arterial oxygen gradient. The chest radiograph shows bilateral diffuse alveolar disease with an air bronchogram. Without treatment, the disease worsens and within a month all patients will have died. Even in fatal cases and even in the most severely compromised host, the organism and the disease remain localized to the lung, with rare exception. When specific and supportive treatment is introduced early in the disease, the mortality rate can be reduced to around 10{\%} in most medical centers. Abrupt onset tends to occur in patients with cancer, organ transplantation, and AIDS.",
author = "Hughes, {Walter T.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1017/CBO9780511722240.179",
language = "English (US)",
isbn = "9780511722240",
pages = "1229--1232",
booktitle = "Clinical Infectious Disease",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Pneumocystis pneumonia

AU - Hughes, Walter T.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The diffuse bilateral pneumonitis caused by Pneumocystis jirovecii (also called Pneumocystis carinii) occurs almost exclusively in immunocompromised patients with cancer, organ transplantation, congenital immunodeficiency disorders, and acquired immunodeficiency syndrome (AIDS). The organism is known to cause pneumonitis occasionally in patients without underlying immunodeficiency. CLINICAL FEATURES: The clinical manifestations of Pneumocystis pneumonitis are fever, cough, tachypnea, and dyspnea progressing to cyanosis. The onset may be abrupt or subtle. With an abrupt onset, fever, marked increase in respiratory rate, and severe dyspnea occur within 24 to 48 hours. The disease progresses rapidly with marked decrease in arterial oxygen tension (PaO2) and increase in alveolar-arterial oxygen gradient. The chest radiograph shows bilateral diffuse alveolar disease with an air bronchogram. Without treatment, the disease worsens and within a month all patients will have died. Even in fatal cases and even in the most severely compromised host, the organism and the disease remain localized to the lung, with rare exception. When specific and supportive treatment is introduced early in the disease, the mortality rate can be reduced to around 10% in most medical centers. Abrupt onset tends to occur in patients with cancer, organ transplantation, and AIDS.

AB - The diffuse bilateral pneumonitis caused by Pneumocystis jirovecii (also called Pneumocystis carinii) occurs almost exclusively in immunocompromised patients with cancer, organ transplantation, congenital immunodeficiency disorders, and acquired immunodeficiency syndrome (AIDS). The organism is known to cause pneumonitis occasionally in patients without underlying immunodeficiency. CLINICAL FEATURES: The clinical manifestations of Pneumocystis pneumonitis are fever, cough, tachypnea, and dyspnea progressing to cyanosis. The onset may be abrupt or subtle. With an abrupt onset, fever, marked increase in respiratory rate, and severe dyspnea occur within 24 to 48 hours. The disease progresses rapidly with marked decrease in arterial oxygen tension (PaO2) and increase in alveolar-arterial oxygen gradient. The chest radiograph shows bilateral diffuse alveolar disease with an air bronchogram. Without treatment, the disease worsens and within a month all patients will have died. Even in fatal cases and even in the most severely compromised host, the organism and the disease remain localized to the lung, with rare exception. When specific and supportive treatment is introduced early in the disease, the mortality rate can be reduced to around 10% in most medical centers. Abrupt onset tends to occur in patients with cancer, organ transplantation, and AIDS.

UR - http://www.scopus.com/inward/record.url?scp=84923401014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923401014&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511722240.179

DO - 10.1017/CBO9780511722240.179

M3 - Chapter

AN - SCOPUS:84923401014

SN - 9780511722240

SN - 9780521871129

SP - 1229

EP - 1232

BT - Clinical Infectious Disease

PB - Cambridge University Press

ER -